Genetics of drug dependence by Gelernter, Joel & Kranzler, Henry R.
t is well established that risk for many sub-
stance-dependence traits is genetically influenced; this is
the case for each specific substance that has been stud-
ied. This has been determined using the methods of
genetic epidemiology, the most relevant of which, for this
purpose, are twin and adoption studies. We discuss rel-
evant findings from genetic epidemiologic studies of
drug use and use disorders below.
In considering drug dependence, we include the most
commonly used illegal substances (primarily cocaine,
opioids, marijuana, and methamphetamine) and also
nicotine, a legal drug that is the dependence-causing sub-
stance in tobacco. Alcohol dependence (AD) shares
many risk genes with the drug-dependence disorders, but
is beyond the scope of the present article. We have
recently reviewed AD genetics elsewhere.
1
As is usual for complex traits, risk for drug dependence is
influenced by both genetic and environmental factors.
Compared with most other kinds of traits though, envi-
ronmental factors, most obviously exposure to the sub-
stance, are crucial—you cannot become heroin-dependent,
for example, if you live in an environment with no access
to heroin. Because the availability of illegal substances of
abuse varies over the world (to a much greater extent than
the availability of either alcohol or tobacco), and also
varies with time as a function of secular trends in substance
use that are determined by fads, trends in law enforcement,
and other factors, patterns of substance dependence are
very different across the globe. Genetic epidemiologic
studies have helped to clarify the important implications
of this environmental variation for genetic studies.
Family studies have shown substantially higher rates of
drug abuse among siblings (particularly those whose par-
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Drug-dependence disorders (we focus here on cocaine,
opioid, and nicotine dependence) are genetically influ-
enced. Risk genes have been located based primarily on
genetic linkage studies, and identified primarily based on
genetic association studies. In this article we review salient
results from linkage, association, and genome-wide asso-
ciation study methodologies, and discuss future prospects
for risk allele identification based on these, and on newer,
methodologies. Although considerable progress has been
made, it is likely that the application of more extensive
sequencing than has previously been practical will be
required to identify a fuller range of risk variants.  
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viduals in the community.
2-5 Such studies have also pro-
vided evidence for both general familial aggregation for
substance-use disorders and substance-specific aggrega-
tion across a wide range of drugs, including nicotine, opi-
oids, cocaine, and cannabis.
6,7 However, while these designs
demonstrate that drug-dependence disorders are familial,
they cannot distinguish between genetic and environmen-
tal contributions to this familiality. A demonstration of
genetic contributions to these and other disorders requires
other designs, prominently twin and adoption studies.
Two adoption studies conducted by Cadoret et al
8,9
showed that the only biological factor that was signifi-
cantly associated with drug abuse in the proband was an
alcohol problem in first-degree relatives. However,
Tsuang et al,
10 studying a sample of more than 3000 twin
pairs, found a significantly greater pairwise concordance
rate for monozygotic (MZ) than dizygotic (DZ) twins
for abuse of marijuana, stimulants, cocaine, and for all
drugs combined. Using twin pairs ascertained through
the Virginia Twin Registry, Kendler et al examined con-
cordance rates for drug use and dependence among
more than 800 female-female pairs.
11-13 Model fitting
showed that twin resemblance for liability to the use of
cocaine, cannabis, hallucinogens, opioids, and sedatives
was due to both genetic and family environmental fac-
tors. Liability to abuse or dependence on cocaine and
cannabis was due only to genetic factors. In contrast,
however, in another study by Kendler et al
14 of the use
and misuse of six classes of illicit drugs by nearly 1200
male-male twin pairs, model fitting revealed that one
common genetic factor exerted a potent influence on
risk for both substance use and misuse for all six sub-
stances. There was a modest effect on risk of substance-
specific genetic factors seen for substance use, but in
contrast to other studies cited above, not for abuse or
dependence. A single common shared environmental
factor was also found to exert an effect on risk of sub-
stance use, and to a lesser extent, on risk of abuse depen-
dence. 
Despite some contradictory findings, overall, the data
from adoption, twin, and family studies support a sub-
stantial genetic contribution to drug dependence, includ-
ing the existence of genetic factors specific to each of
these disorders, and factors common to these disorders
and other forms of substance dependence.
It is only common genetic factors (that is, those that
influence more than one substance) that are likely to be
important worldwide (genetic factors specific to sub-
stances will vary because the specific substances vary).
Whether genes relevant to drugs of abuse that have
some similarities in their mechanisms of action, such as
cocaine (important, eg, in the US) and methampheta-
mine (predominant, eg, in Thailand, and important in
certain regions in the US) will prove to overlap, is still
an open question. Further, different risk factors may be
important in different populations (discussed in ref 1).
In the small number of instances where similar SD traits
have been studied in different populations, the genetic
factors uncovered have not been identical.
Thus, gene mapping for substance-dependence (SD)
traits is complicated. Some risk alleles identified may be
important only for specific substances of abuse and oth-
ers, only for certain populations. So why try to map
genes for SD traits? First, SD is a huge cause of mor-
bidity and mortality worldwide; that is, it is a very impor-
tant problem that deserves to be studied despite its com-
plexity. Second, despite all of the a priori reasons to
believe that it would be exceedingly difficult to identify
genes and validate the findings, the track record for SD
genetics as a field is really very good. Below, we will
review some recent results that support this claim.
Linkage studies
Genome-wide linkage studies, the traditional approach
to identifying risk loci, provide chromosomal locations
for risk-influencing loci based on the observation of
coinheritance of marker alleles and the disease trait in
families. To be comprehensive, linkage studies employ
markers that map throughout the entire genome. This
approach has been used for cocaine, opioid, and nicotine
dependence, and for related traits. 
We are aware of only one linkage study of cocaine
dependence (CD); we studied a sample of small families
Pharmacological aspects
78
Selected abbreviations and acronyms
AA African-American
AD alcohol dependence
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ND nicotine dependence
OD opioid dependence
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included 528 full and 155 half sibpairs and was 45.5%
European-American (EA) and 54.5% African-
American (AA).
15We completed an autosomal genome-
wide linkage scan for the CD diagnosis, cocaine-induced
paranoia, and cocaine-related subphenotypes derived
using cluster analytic methods. The subtyping procedure
was used to identify more genetically homogeneous sub-
groups of subjects in which the effects of individual risk
loci might be more prominent. For CD, we found “sug-
gestive” linkage signals on chromosome 10, in the full
sample, and on chromosome 3, in the EA part of the
sample. Much stronger results were obtained for the
cluster-derived subtypes, including genome-wide-
significant lod scores for membership in the “Heavy Use,
Cocaine Predominant” cluster on chromosome 12 and
for membership in the “Moderate Cocaine and Opioid
Abuse” cluster on chromosome 18. In AA families only,
we observed a genome-wide-significant lod score on
chromosome 9 for the trait of cocaine-induced paranoia.
Genome-wide significance was defined on the basis of
Lander and Kruglyak's 1995 criteria.
16
There have been three independent genome-wide link-
age studies of opioid dependence (OD). We studied 393
small families each with at least one individual affected
with OD.
17We completed a genome-wide linkage scan for
DSM-IV OD, and, as for the CD study, for cluster-
defined phenotypes, a heavy-opioid-use cluster, and a
non-opioid-using cluster. The strongest results were,
again, seen with the cluster-defined traits: for the “heavy
opioid users” cluster there was a genome-wide-
significant linkage for EA and AA subjects combined, on
chromosome 17. For the “nonopioid users” cluster, there
was a genome-wide-significant linkage elsewhere on
chromosome 17, for EA subjects only. Lachman et al
18
studied a mixed US sample of 305 OD-affected sibling
pairs, and identified evidence for linkage on a region of
chromosome 14 overlying the neurexin 3 gene (NRXN3).
They also identified a male-specific linkage peak on chro-
mosome 10q. Finally, Glatt et al
19 studied a sample of
nearly 400 independent affected sibling pairs ascertained
in China near the Golden Triangle, one of Asia's largest
illicit opium-producing areas, but did not identify any
strongly-supported linkage signals, despite the presumed
genetic homogeneity of the sample. The strongest signal
they observed was on chromosome 4q.
There have been numerous genome-wide linkage scans for
smoking and related phenotypes, reviewed in ref 20. Han
et al
21 completed genome scan meta-analysis (GSMA) of
genome-wide linkage scans for nicotine dependence (ND)
and related traits, pooling all available independent
genome scan results on smoking behavior. To minimize
locus heterogeneity, subgroup analyses of the smoking
behavior assessed by the Fagerstrom Test for Nicotine
dependence (FTND) and maximum number of cigarettes
smoked in a 24-hour period (MaxCigs24) were also car-
ried out. Fifteen genome scan results were available for
analysis, including 10 253 subjects in 3 404 families. The pri-
mary GSMA across all smoking behavior identified a
genome-wide “suggestive” linkage in chromosome
17q24.3-q25.3. But the strongest result derived from the
subgroup analysis of MaxCigs24 (including 966 families
with 3 273 subjects), which identified a genome-wide sig-
nificant linkage in 20q13.12-q13.32. CHRNA4, a strongly
supported ND candidate gene, is located in this interval;
Li et al
22 previously reported on association of CHRNA4
variants to ND.
A high level of statistical support for a genetic linkage is
very valuable, but the ultimate proof that a disease-influ-
encing locus underlies a statistical linkage peak is the
identification of a risk gene in the peak that accounts for
the linkage signal. The next step is typically genetic asso-
ciation analysis, ie, evaluation of a set of markers that
map under the linkage peak for association with the
trait. Genetic association provides another degree of sta-
tistical evidence, but eventually, proof of a disease-gene
relationship must rely on demonstration of a functional
effect of a variant or variants at the risk locus. ND is the
furthest of all drug-dependence (DD) traits along this
pathway, with numerous loci supported on the basis of
statistical genetic association evidence, and some of
these loci have received the higher level of support of
functional data.
Association studies
Strategy for single-nucleotide polymorphism (SNP)
selection plays a key role in association study outcome.
In general, variants predicted to have functional conse-
quences, eg, because they alter predicted amino acid
sequence, have been favored for study; alternatively,
researchers often try to capture most of the genetic vari-
ation at a locus via selection of haplotype tagging SNPs
followed by haplotype reconstruction. It is important to
recognize some of the limitations of these strategies at
the outset. Although most common putatively functional
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effects, and there are many such variants yet to be dis-
covered. Not all functional SNPs are easily recognized
as such. SNPs vary by population, and populations dif-
fer in the extent to which common genetic variation has
been identified. The same population variation is
reflected in differences in haplotype structure. Finally,
haplotype reconstruction is almost always accomplished
via computer algorithms, and the results are estimated.
With these limitations in mind, we discuss several exam-
ples of genetic associations with DD phenotypes, focus-
ing on interesting physiological candidates and on repli-
cated findings. 
Association of variants that map at or near the D2
dopamine receptor (DRD2 locus) with drug or alcohol
dependence was proposed many years ago and has been
widely debated. We identified a “suggestive” linkage peak
for ND at the region of chromosome 11 that includes the
NCAM1-TTC12-ANKK1-DRD2 gene cluster.
23 The
inconsistent results with DRD2 may be attributable to an
indirect effect—observed association could actually be
mediated through variation at a nearby locus in linkage
disequilibrium with DRD2. To test this hypothesis, we
genotyped 43 SNP markers in a region including DRD2
and the three adjacent genes, in an SD linkage sample of
>1600 subjects. We found very strong evidence of associ-
ation of multiple SNPs at TTC12 and ANKK1 in two dif-
ferent populations, EAs and AAs (minimal P=0.0007 in
AAs and minimal P=0.00009 in EAs), and highly signif-
icant association of a single haplotype (set of markers)
spanning TTC12 and ANKK1 to ND in the pooled sam-
ple (P=0.0000001). Thus, a risk locus for ND maps to a
region that spans TTC12 and ANKK1. The exact local-
ization of the risk haplotype depends on the disease def-
inition, and whether and which co-occurring diagnoses
are present in the study sample.
24
These results support the hypothesis that the DRD2
findings could be attributable to variants in nearby loci.
Such variants could reflect either functional variation
that affect those loci (and not DRD2), or relatively dis-
tant regulatory regions important for DRD2 function.
The ANKK1 finding in ND has been replicated.
25
Another set of risk loci that are of interest in relation to
the risk of drug dependence are those encoding proteins
that regulate or mediate opioidergic function. All of the
opioid receptor genes have been reported to be associ-
ated with substance dependence liability. A functional
polymorphism in OPRM1 (Asn40Asp), which encodes
the mu-opioid receptor, has been the most extensively
studied in this regard, though the association is contro-
versial. Although multiple studies have shown a signifi-
cant allelic association with DD, they are nearly evenly
divided between those showing a significant excess of
the Asp40 allele among cases
26,27 and those showing a sig-
nificant excess of the Asp40 allele among controls.
28-30
Consequently, meta-analyses of that literature failed to
show a reliable association of the SNP with either OD
31
or any SD disorder.
32 However, Zhang et al
33 examined
13 SNPs spanning the coding region of OPRM1 in a
sample of EAs with AD and/or DD and 338 EA healthy
controls. The SNPs formed two haplotype blocks. There
were significant differences between cases and controls
in allele and/or genotype frequencies for SNPs in Block
I and in Block II, after correction for multiple testing.
Haplotypes constructed from five tag SNPs differed sig-
nificantly in frequency between both AD and DD sub-
jects and controls. Logistic regression analyses in which
the sex and age of subjects and alleles, genotypes, hap-
lotypes, or diplotypes of the five tag SNPs were consid-
ered confirmed the association between OPRM1 vari-
ants and SD. 
Zhang et al
34 also examined the genes encoding the
other two opioidergic receptors: OPRD1 (which encodes
the delta receptor) and OPRK1 (which encodes the
kappa receptor). Eleven SNPs spanning OPRD1 were
examined in EAs with AD, CD, and/or OD, and control
subjects. Although nominally significant associations
were observed for five SNPs with SD, only the associa-
tion of the nonsynonymous variant G80T with OD
remained significant after correction for multiple test-
ing. Haplotype analyses with six tag SNPs indicated that
a specific haplotype was significantly associated with AD
and OD (P<0.001). In logistic regression analyses, con-
trolling for sex and age, this haplotype had a risk effect
on AD and, to a much greater extent, on OD. In addi-
tion, seven SNPs covering OPRK1 were examined in the
majority of subjects and although there were no signif-
icant differences in allele, genotype, or haplotype fre-
quency distributions between cases and controls, a spe-
cific OPRK1 haplotype was significantly associated with
AD, but not DD. In summary, these findings demon-
strated a robust positive association between OPRD1
variants and SD, particularly OD. 
Finally, Zhang et al
35 studied POMC, the gene that
encodes pro-opioimelanocortin, from which functionally
different peptides are derived via tissue-specific post-
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two principal elements of the hypothalamic-pituitary-
adrenal axis: adrenocorticotropin (ACTH) and β-endor-
phin. Five SNPs spanning POMC were examined in
independent family and case-control samples of EAs
and AAs. The families were ascertained based on a pair
of siblings affected with cocaine and/or opioid depen-
dence. Case-control studies included cases affected with
AD, CD and/or OD and controls. Family-based analyses
revealed an association of one SNP (rs6719226) with
OD in AA families, and a different SNP (rs6713532)
with CD in EA families. Case-control analyses demon-
strated an association of rs6713532 with AD or CD.
Moreover, the minor allele of a third SNP was a risk fac-
tor for CD or OD in AAs, and for AD, CD, or OD in
EAs. Logistic regression analyses in which sex and age
were considered and population stratification analyses
confirmed these findings. Additionally, specific haplo-
types increased risk for CD in AAs and OD in EAs. 
In summary, as might be expected given that the brain’s
opioidergic system plays a central role in reinforcement,
which has important implications for addiction,
36 varia-
tion in a number of functional candidate genes encoding
opioidergic proteins have been implicated in depen-
dence on alcohol, cocaine, and opioids. Assuming inde-
pendent replication of these findings, a key question to
be addressed is the nature of gene-gene and gene by
environment interactions to which risk of SD is attrib-
utable.
Other studies have demonstrated associations with the
cannabinoid receptor gene (CNR1),
37-39 neurexin 1
(NRXN1),
40 and a set of alcohol-metabolizing
enzymes.
41 A clear pattern emerges from the examina-
tion of this sampling of candidate gene associations with
SD: insofar as genes with known function are con-
cerned, there are no big surprises with respect to phys-
iology. (This can not be said about genes without clearly
delineated functional roles, such as ANKK1, which was
identified, not incidentally, based on its position, rather
than its function.) This highlights the limitations of the
candidate gene approach, which is often inherently
biased by prior knowledge about physiology. Unbiased
studies have greater potential to reveal new mecha-
nisms of addiction, and that is a key attraction of the
genome-wide association study (GWAS) methodology
discussed below.
GWASs are an alternative to linkage for locating genes
anywhere in the genome without prior hypotheses.
GWAS designs are of interest due to their potential to
identify risk loci of relatively small effect, much smaller
than through linkage strategies. (In fact, one controversy
engendered by the widespread adoption of GWAS
designs is that often risk alleles are identified that have
such a small effect—typically with odds ratios less than
1.2—that it is hard to know what to do with them once
they have been identified.) A second advantage of
GWASs is that they may be based on case-control sam-
ples, which are easier to recruit than family sampling
schemes, which must be deployed to prepare for linkage.
Family samples are more difficult to recruit (markedly
so for many kinds of SD because of the tendency of
these disorders to fragment families) and can introduce
certain kinds of bias. The first GWAS for a specific SD
trait, excluding studies that used a pooling methodology
exclusively (see ref 42), examined ND.
43 This study
employed a two-stage design; first pooled DNA was
used to screen 2.4 million SNPs; second, >30 000 SNPs
selected from the first stage were screened individually
in ~1000 each cases and controls. Numerous genes were
identified as possibly associated to ND, including both
novel genes and genes that were previously considered
candidates based on known physiology (eg, cholinergic
receptor, nicotinic, beta 3, CHRNB3). The latter finding
has been confirmed in larger studies: subsequent
GWASs have demonstrated highly significant associa-
tions between variation in the nicotinic receptor gene
cluster  CHRNA5-CHRNA3-CHRNB4 and ND and
related traits
44,45 and with lung cancer.
46,47
In a hypothesis-generating study, we studied a set of
5633 SNP markers in 1699 subjects from 339 AA fami-
lies and 334 EA families ascertained through a sib pair
meeting DSM-IV criteria for either CD or OD. This is
considered a sparse marker set for the purposes of
GWAS. It is expected to interrogate <10% of the
genome, thus, cannot be considered to be a study of truly
genome-wide depth. Associations between these mark-
ers and five substance dependence traits (CD, OD, AD,
ND, and cocaine-induced paranoia) were assessed by
family-based association tests (FBAT). The top-ranked
result was an association of a specific SNP in the
MANEA gene with cocaine-induced paranoia. This
study provided an initial SD trait-specific blueprint of
associated regions for future candidate gene studies.
There are, at the time of this writing, no published
GWAS studies for several of these traits. The MANEA
finding was replicated and extended in a larger sample.
48
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We identify two main ways to account for the relatively
consistent results seen in this field. First, diagnosis can
be made with high reliability. Second, the phenotypes are
relatively straightforward because they are, in their
essence, pharmacogenetic. That is, SD phenotypes reflect
genetic moderation of the subjective response to drugs
of abuse.
While results in this research field have been relatively
consistent, most of the genetic risk for DD has yet to be
attributed to specific alleles. Initially, it was thought that
the GWAS was the answer to the problem. But applica-
tion in other complex traits (eg, schizophrenia, bipolar
affective disorder, autism) has revealed a more complex
picture, such that even clinical samples that should have
been adequately powered have fallen short of providing
definitive and significant results. The explanation for this
situation may reside in the fundamental genetic archi-
tecture of some complex traits. GWAS is based on a
common-disease-influenced-by-common-allele model.
However, we are now learning that many phenotypes
are influenced instead by sets of variants, in sets of loci,
each of which is rare on a population level. Such variants
are likely to be uncovered only by extensive sequencing
of affected and unaffected individuals. Copy number
variation (CNV) is another mechanism that is proving
to be important in modulating disease risk. Such varia-
tion is important for at least some behavioral traits; for
example, Sebat et al
49 have reported on the relationship
of CNV to autism, and several groups have reported
association of rare structural variants with schizophre-
nia.
50-53
We have seen several successful examples of genetic
association identified following a linkage finding, a
sequence that demonstrates the main utility of genetic
linkage. But there have also been surprisingly many
instances when strong genetic association has not been
identified readily. There are many ways to account for
such a circumstance—genetic heterogeneity, random
variation, and population variation, to name a few.
Another intriguing possibility has become more promi-
nent of late. The linkage-to-association-to-gene model is
premised basically on the common disease-common
variant model discussed above. This model may not be
as applicable as was thought; there is increasing evidence
that heritability may be accounted for by many rare vari-
ants in either a single locus, or a set of related loci. Since
linkage depends on the identification of coinheritance
of trait and marker within families, it stands to reason
that a set of different rare variants could be detected by
linkage (even if the responsible variants differed greatly
between families in the discovery set). Such variants
would be very resistant to discovery by ordinary tagging
haplotype association strategies. Similarly, such variants
would be expected to be refractory to discovery by
GWAS methodology. Deep sequencing studies have suc-
cessfully accounted for the “missing” genetic variance in
some cases. For example Nejentsev et al
54 found a set of
individually rare variants at the IFIH1 locus that affect
risk for type 1 diabetes, following up on a GWAS study.
Ji et al
55 started with a set of genes known to have large
effects on blood pressure in a small number of severely
affected families, and sequenced them in a large number
of unrelated individuals. Rare variants with smaller
effects on blood pressure were identified. These findings
are likely to be relevant for SD genetics research as well,
inasmuch as deep sequencing of candidate loci in many
unrelated individuals may be necessary to account for a
greater proportion of the genetic risk than is presently
known.
Whole-genome sequencing is becoming progressively
less expensive, and will surely ultimately be feasible for
locating genetic variants that increase risk for complex
genetic traits, albeit at the risk of daunting statistical
problems. Sequencing of expressed sequences only
(‘whole exome”) may be a valuable interim step. Ng et
al
56 have demonstrated the feasibility of this approach.
In summary, new developments in a variety of genetic
methods and in the accumulating molecular evidence of
the genetic risk for SD promise to yield greater insights
into the etiology of these disorders, bringing into relief
the environmental contributions and creating opportu-
nities for prevention and new therapeutic options. ❏
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Genética de la dependencia de drogas
Los trastornos de dependencia de drogas (aquí se
revisa cocaína, opioides y nicotina) tienen una
influencia genética. Primariamente la localización
de los genes de riesgo se ha basado en estudios de
ligamiento y la identificación en estudios de aso-
ciación genética. En este artículo se revisan resulta-
dos destacados sobre metodologías de estudio de
ligamiento, asociación y asociación del genoma
completo y se discuten las posibilidades futuras
para la identificación del riesgo de alelos en base a
estas y otras metodologías más recientes. Aunque
se ha realizado un progreso considerable, es pro-
bable que la aplicación de secuenciaciones más
amplias que las que se han practicado previamente
serán requeridas para identificar un mayor rango
de variantes de riesgo. 
Génétique de la toxicomanie
Il existe une prédisposition génétique à la toxico-
manie (dans cet article, nous nous intéresserons à
la dépendance à la cocaïne, aux opioïdes et à la
nicotine). Des gènes de ce risque ont été localisés
initialement  à partir d’études de liaisons géné-
tiques et identifiés à partir d’études d’association
génétique. Nous présentons dans cet article les prin-
cipaux résultats issus d'études d’association sur le
génome entier, de liaisons et d’associations ainsi
que les perspectives d’identification d’un allèle du
risque fondées sur ces méthodologies et de  plus
récentes. Malgré des progrès considérables, un
séquençage plus étendu que celui effectué aupara-
vant sera probablement nécessaire pour identifier
une gamme plus complète de variants du risque.
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